Evidence map›Paper›PMID 32357907›Full record

ArticleBreast cancer research : BCR2020

Glucocorticoid receptors are required effectors of TGFβ1-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer.

Carlos Perez Kerkvliet, Amy R Dwyer, Caroline H Diep, Robert H Oakley, Christopher Liddle, John A Cidlowski, Carol A Lange

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Carlos Perez KerkvlietDepartments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology, University of Minnesota Masonic Cancer Center, Delivery Code 2812 Cancer and Cardiovascular Research Building; Suite 3-126 2231 6th St SE, Minneapolis, MN, 55455, USA.
Amy R DwyerDepartments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology, University of Minnesota Masonic Cancer Center, Delivery Code 2812 Cancer and Cardiovascular Research Building; Suite 3-126 2231 6th St SE, Minneapolis, MN, 55455, USA.
Caroline H DiepDepartments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology, University of Minnesota Masonic Cancer Center, Delivery Code 2812 Cancer and Cardiovascular Research Building; Suite 3-126 2231 6th St SE, Minneapolis, MN, 55455, USA.
Robert H OakleyDepartment of Health and Human Services, Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 27709, USA.
Christopher LiddleStorr Liver Centre, The Westmead Institute for Medical Research and Westmead Hospital, University of Sydney, Darlington, NSW, 2006, Australia.
John A CidlowskiDepartment of Health and Human Services, Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 27709, USA.
Carol A LangeDepartments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology, University of Minnesota Masonic Cancer Center, Delivery Code 2812 Cancer and Cardiovascular Research Building; Suite 3-126 2231 6th St SE, Minneapolis, MN, 55455, USA. lange047@umn.edu.
Minnesota Oncology · USNational Institute of Environmental Health Sciences · USUniversity of Minnesota · USWestmead Institute for Medical Research · AU

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
GLUCOCORTICOID HORMONE ACTIONZ01ES090057 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI CIDLOWSKI, JOHN A. · 1996 to 2008
$4.1M
Inducible PTK6 expression drives oncogenic signaling in breast cancerR01CA192178 · NCI · UNIVERSITY OF MINNESOTA · PI LANGE, CAROL A · 2015 to 2019
$2.2M
PhosphoSer134 GR, TGF-β and 14-3-3-zeta cooperate to promote progression of Triple Negative Breast CancerF30CA228261 · NCI · UNIVERSITY OF MINNESOTA · PI PEREZ KERKVLIET, CARLOS JESUS · 2019 to 2021
$152k
Intramural NIH HHS Z01 ES090057NCATS NIH HHS UL1 TR002494NCI NIH HHS F30 CA228261NCI NIH HHS R01 CA192178NCI NIH HHS T32 CA009138NIGMS NIH HHS T32 GM008244
6 · The paper itself

Abstract

backgroundAltered signaling pathways typify breast cancer and serve as direct inputs to steroid hormone receptor sensors. We previously reported that phospho-Ser134-GR (pS134-GR) species are elevated in triple-negative breast cancer (TNBC) and cooperate with hypoxia-inducible factors, providing a novel avenue for activation of GR in response to local or cellular stress.

methodsWe probed GR regulation by factors (cytokines, growth factors) that are rich within the tumor microenvironment (TME). TNBC cells harboring endogenous wild-type (wt) or S134A-GR species were created by CRISPR/Cas knock-in and subjected to transwell migration, invasion, soft-agar colony formation, and tumorsphere assays. RNA-seq was employed to identify pS134-GR target genes that are regulated both basally (intrinsic) or by TGFβ1 in the absence of exogenously added GR ligands. Regulation of selected basal and TGFβ1-induced pS134-GR target genes was validated by qRT-PCR and chromatin immunoprecipitation assays. Bioinformatics tools were used to probe public data sets for expression of pS134-GR 24-gene signatures.

resultsIn the absence of GR ligands, GR is transcriptionally activated via p38-dependent phosphorylation of Ser134 as a mechanism of homeostatic stress-sensing and regulated upon exposure of TNBC cells to TME-derived agents. The ligand-independent pS134-GR transcriptome encompasses TGFβ1 and MAPK signaling gene sets associated with TNBC cell survival and migration/invasion. Accordingly, pS134-GR was essential for TNBC cell anchorage-independent growth in soft-agar, migration, invasion, and tumorsphere formation, an in vitro readout of cancer stemness properties. Both pS134-GR and expression of the MAPK-scaffolding molecule 14-3-3ζ were essential for a functionally intact p38 MAPK signaling pathway downstream of MAP3K5/ASK1, indicative of a feedforward signaling loop wherein self-perpetuated GR phosphorylation enables cancer cell autonomy. A 24-gene pS134-GR-dependent signature induced by TGFβ1 predicts shortened overall survival in breast cancer patients.

conclusionsPhospho-S134-GR is a critical downstream effector of p38 MAPK signaling and TNBC migration/invasion, survival, and stemness properties. Our studies define a ligand-independent role for GR as a homeostatic "sensor" of intrinsic stimuli as well as extrinsic factors rich within the TME (TGFβ1) that enable potent activation of the p38 MAPK stress-sensing pathway and nominate pS134-GR as a therapeutic target in aggressive TNBC.

Indexed as

betaIG-H3 ProteinBiomarkers, TumorCell Line, TumorCell MovementExtracellular Matrix ProteinsFemaleGene EditingHumansNeoplasm Stagingp38 Mitogen-Activated Protein KinasesPhosphorylationReceptors, GlucocorticoidTranscriptomeTransforming Growth Factor betaTriple Negative Breast NeoplasmsTumor MicroenvironmentbetaIG-H3 ProteinBiomarkers, TumorExtracellular Matrix Proteinsp38 Mitogen-Activated Protein KinasesReceptors, GlucocorticoidTransforming Growth Factor beta14-3-3ζBreast cancerCellular stressCytokinesGlucocorticoid receptorMAP3K5/ASK1Migrationp38 MAP kinasePhosphorylationTGFβ1Transcription

Identifiers

PMID32357907
PMCPMC7193415
OpenAlexW3023645923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.